

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



STARCOIN GROUP LIMITED

星太鏈集團有限公司

*(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

(Stock Code: 399)

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE AMENDMENT TO THE TERMS AND CONDITIONS OF THE CONVERTIBLE BONDS AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL AND CONTINUED SUSPENSION OF TRADING

References are made to the announcements of the Company dated 2 December 2025, 27 February 2026 and 29 May 2026 in relation to, among others, the Fourth Amendments to the terms and conditions of the Convertible Bonds issued by the Company to Extrawell Pharmaceutical Holdings Limited as the Bondholder (collectively, the “**Announcements**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

FURTHER DELAY IN DESPATCH OF CIRCULAR

As stated in the Announcements, the Circular containing, amongst other things, (i) further details of the Fourth Deed of Amendment and the transactions contemplated thereunder; and (ii) a notice of the SGM to be convened and held for the Shareholders to consider and, if thought fit, to approve the Fourth Amendments and the transactions contemplated thereunder is expected to be despatched to the Shareholders on or before 11 September 2026 in accordance with the Listing Rules.

As additional time is required to fulfil the conditions precedent set out in the Fourth Deed of Amendment, the Company and the Bondholder are currently discussing a further extension of the relevant date. In light of these ongoing discussions, and additional time is required for the Company to prepare and finalise certain information for inclusion in the Circular, the despatch date of the Circular has been postponed to a date on or before 15 November 2026.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 6 May, 2026 and will remain suspended until further notice. The Company will make further announcement(s) as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 11 September 2026

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.